Novo Nordisk (NVO) shares gain after the pharmaceutical company’s earnings beat on the bottom and top lines despite warnings of slower growth. Novo Nordisk CEO Lars Fruergaard Jørgensen sits down with Yahoo Finance Senior Reporter Anjalee Khemlani to discuss the results and the company’s outlook. "It has been a tremendous run over quite a period now, and, we’re really pleased with the 26% growth we saw in [2024] when we guide a bit lower for the coming year, it’s really because that we grow on a larger base," Fruergaard Jørgensen says. "It looks like a lower relative growth, but it’s actually the same absolute growth that we see in the coming year," the CEO adds, explaining, "We are ramping up capacity significantly [and] our guidance includes a significant step up in supply. We are already the absolute volume leader in the GLP-1 category, having approximately twice the volume of competition going to the market. And we keep scaling on top of that, and we see a continued large demand in the market." Amid uncertainty about US President Donald Trump’s tariff policies and the other impacts of his administration, Fruergaard Jørgensen highlights the prominence of Novo Nordisk’s GLP-1 weight-loss drugs and its other pharmaceutical offerings.
#youtube #stocks #investing
About Yahoo Finance:
Yahoo Finance provides free stock ticker data, up-to-date news, portfolio management resources, comprehensive market data, advanced tools, and more information to help you manage your financial life.
– Get the latest news and data at finance.yahoo.com
– Download the Yahoo Finance app on Apple (https://apple.co/3Rten0R) or Android (https://bit.ly/3t8UnXO)
– Follow Yahoo Finance on social:
X: http://twitter.com/YahooFinance
Instagram: https://www.instagram.com/yahoofinance/?hl=en
TikTok: https://www.tiktok.com/@yahoofinance?lang=en
Facebook: https://www.facebook.com/yahoofinance/
LinkedIn: https://www.linkedin.com/company/yahoo-finance
